A Noncanonical MET Exon 14 Splice-Site Variant in Pulmonary Sarcomatoid Carcinoma With Response to Capmatinib

  • Oh, Hyung-Joo; 
  • Choi, Yoo-Duk; 
  • Choi, Yoon-La; 
  • Park, Ha-Young; 
  • Yoon, Joon-Young; 
  • 외 5명
Citations

WEB OF SCIENCE

0
Citations

SCOPUS

0

초록

MET exon 14 skipping is an actionable oncogenic driver in non-small cell lung carcinoma (NSCLC); however, noncanonical splice-region variants are frequently classified as variants of unknown significance (VUS), which may result in missed therapeutic opportunities and highlight limitations in current DNA next-generation sequencing (NGS) reporting criteria. We report a patient with pulmonary sarcomatoid carcinoma harboring a noncanonical MET splice donor-proximal indel (c.3022_3028 + 13delinsA), initially interpreted as a VUS, who achieved a rapid and durable response to capmatinib. Subsequent RNA sequencing and droplet digital PCR (ddPCR) confirmed MET exon 14 skipping, supporting the value of orthogonal transcript-level validation for exon-adjacent variants.

키워드

capmatinib; case report; MET; sarcomatoid carcinoma; CELL LUNG-CANCER; MUTATIONS
제목
A Noncanonical MET Exon 14 Splice-Site Variant in Pulmonary Sarcomatoid Carcinoma With Response to Capmatinib
저자
Oh, Hyung-Joo; Choi, Yoo-Duk; Choi, Yoon-La; Park, Ha-Young; Yoon, Joon-Young; Kim, Jang-Hyeon; Lim, Jung-Hwan; Park, Cheol-Kyu; Oh, In-Jae; Kim, Young-Chul
DOI
10.1111/1759-7714.70371
발행일
2026-08-07
유형
Article
저널명
Thoracic Cancer
권
17
호
15